•  
  • Our History
  • Product History
  • Certifications
•  
  • Technical Bulletins & Documents
  • Respiratory Links
•  
  • Oxyview®
    • About Oxyview®
    • Purchase Oxyview®
    • Specifications
    • Instructions For Use
    • Reimbursement Codes
    • Testimonials
    • Video Presentation
    • Manufacturing Oxyview®
    • Brochure
  • PogaMoonga
    • About PogaMoonga
    • Purchase PogaMoonga
•  
  • Distributor Locations
  • Group Purchasing Organizations
  • OEM Partners
•  
  • Contact Information
  • Customer Feedback
  • Distributor Inquiry
•  
  • Corporate Compliance Program
  • Privacy Policy
  • Investor Relations
    • Letter From The Chairman
    • Management
    • Board Of Directors
    • SEC Filings
    • Stock Quotes & Press Releases
    • Investor FAQ
    • Investor Inquiry
    • Corporate Governance

INGEN TECHNOLOGIES, INC.
Ingen Technologies Receives FDA Export Certification for China
 

For Release Thursday, September 23, 2008

YUCAIPA, Calif., Sept. 23, 2008 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:ITEC), an emerging medical device manufacturer within the $4-Billion respiratory device market, announced today that the Food & Drug Administration has provided the Export Certification to market and sell Oxyview(r) within Taiwan and the People's Republic of China.

There are significant needs for Oxyview(r) in the home health care and hospital care setting. The company currently has distribution contracts in Asia to purchase a minimum of 120,000 Oxyview(r) units annually, commencing upon the completion of the Taiwan and China registrations. Both of these registrations are close to completion. The governments of Taiwan and People's Republic of China have accepted the Export Certifications provided by the U.S. Food and Drug Administration. This represents approximately $1-M in additional annual revenue for Ingen with net profits of more than $500,000.

The People's Republic of China has 1.3B population with an expanding modernized health care system. The life expectancy is age 73, and the economy GDP is about $7-Billion. The population over 65 years of age represents 10% of the total population, and this is the market for Ingen's respiratory product line. According to a report published in Science Daily on October 15, 2007, in China, chronic obstructive pulmonary disease (COPD) in people over the age of 40 is much more prevalent than previously thought. Of the more than 20,000 who completed these materials, 8.2% of respondents over 40 met the criteria for having COPD. Men were more than twice as likely to have COPD as women. But while smoking was, and is, a significant risk factor for COPD in China, only 24% of the females with COPD were smokers, as opposed to nearly 82% of males, suggesting that women's risk might be more strongly associated with the use of biomass fuels, especially for cooking in poorly ventilated areas.

For more information please visit:
http://www.ingen-tech.com
http://healthcare-economist.com/2008/08/13/olympic-post-iii-china-and-india-healthcare-statistics/
http://www.sciencedaily.com/releases/2007/10/071012080126.htm

About Ingen Technologies, Inc.

Ingen is an emerging public company that introduced Oxyview(r) into the respiratory market in 2007; the world's first in-line oxygen flow meter. The company has expanded its distribution in North America and Asia, all of which reflect a multitude of cultures, nationalities, religions, expertise and ideas. Ingen has branded the Oxyview(r) with every major professional publication, and has gained the support from national recognized affiliates. The Company continues to adopt new OEM partners and expand the hospital based Group Purchasing Organizations as a part of the expansion program for distribution. According to the 2002 CDC Report, there are approximately 32 million people living in the United States that suffer from Chronic Obstructive Pulmonary Disease, more commonly known as "COPD". COPD is the major cause of hospitalizations and the fifth leading cause of death in the United States. A large portion of the COPD patients receive oxygen therapy. Ingen Technologies owns the patents and trademarks for Oxyview(r) and OxyAlert(r), and there are no other products that compete or simulate either of these two products within the medical industry.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

• Ingen Technologies, Inc.
  Chris Wirth, Director
  (909) 790-7180
  Fax: (909) 795-6340
  [email protected]
  35193 Avenue "A"
  Yucaipa, California 92399